Abstract:BACKGROUND:Lung adenocarcinoma (LUAD) accounts for the largest proportion of lung cancer patients and has the highest morbidity and mortality worldwide. Accumulating evidence shows that immune-associated long non-coding RNAs (lncRNAs) play a role in LUAD, although their predictive value for immunotherapy treatment and cancer-related death remains poorly investigated.METHODS:Gene expression profiles and clinical data were obtained from The Cancer Genome Atlas. We constructed a risk model by univariate and multivariate Cox regression and least absolute shrinkage and selection operator regression analysis and subsequently divided each sample into low- or high-risk category. Survival and receiver operating characteristic (ROC) analyses were applied to assess the prognostic value of the model. Additionally, immune and somatic mutation status were analysed between the two risk groups. Finally, the model was applied to pancreatic ductal adenocarcinoma (PDAC) samples to explore the applicability of the model in other cancers.RESULTS:We obtained data from 499 LUAD patients and randomised the samples into a training set (N=351) and validation set (N=148) at a 7:3 ratio. We detected 7 immune-associated lncRNAs (AP000695.2, AC026355.2, LINC01843, ITGB1-DT, LINC01150, AL590226.1 and AC091185.1) that were applicable for establishing a risk signature. Survival analysis revealed that patients categorised in the high-risk group had shorter overall survival (OS) than those in the low-risk group. ROC analyses showed excellent AUC values in all data sets (>0.65 at 1, 3, and 5 years). Notably, ESTIMATE algorithm and analysis of PCA, (ss)GSEA, and somatic mutations revealed that the high-risk group had a stronger immunosuppressive status and a higher tumour mutation burden (TMB). Moreover, patients in the low-risk group responded better to immunotherapy due to higher levels of immune-checkpoint receptor genes and TLS-related genes. Our model using the 7 immune-associated lncRNAs showed similar applicability for PDAC patients.CONCLUSIONS:We constructed a model for risk signatures based on 7 immune-associated lncRNAs and showed its prognostic value for identifying immune and somatic mutation characteristics in LUAD patients, which may assist clinical treatment plans and elucidate molecular mechanisms of LUAD immunity.

Identification of Stage-Specific Biomarkers in Lung Adenocarcinoma Based on Rna-Seq Data

Identification of Stage-associated MicroRNAs in Lung Adenocarcinoma Based on Microarray Data

Interactive Verification Analysis of Multiple Sequencing Data for Identifying Potential Biomarker of Lung Adenocarcinoma

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

Identification of Three Lncrnas As Potential Predictive Biomarkers of Lung Adenocarcinoma

Varied Pathways of Stage Ia Lung Adenocarcinomas Discovered by Integrated Gene Expression Analysis

Genome-scale analysis to identify prognostic markers and predict the survival of lung adenocarcinoma.

Identification of immune regulatory protein-coding genes in the development of lung adenocarcinoma (LUAD)

Integrated Analysis of Long Non-Coding RNA-associated Cerna Network Reveals Potential Lncrna Biomarkers in Human Lung Adenocarcinoma

Identification of prognostic candidate signatures by systematically revealing transcriptome characteristics in lung adenocarcinoma with differing tumor microenvironment immune phenotypes

Identification of TNM stage-specific genes in lung adenocarcinoma by genome-wide expression profiling.

Identification of Biomarkers for the Detection of Early Stage Lung Adenocarcinoma by Microarray Profiling of Long Noncoding RNAs.

LncRNA LINC01833 is a Prognostic Biomarker and Correlates with Immune Infiltrates in Patients with Lung Adenocarcinoma by Integrated Bioinformatics Analysis

Identification of Immune-Associated Lncrnas As a Prognostic Marker for Lung Adenocarcinoma.

Identification of potential key molecular biomarkers in lung adenocarcinoma by bioinformatics analysis

The Screening of Immune-Related Biomarkers for Prognosis of Lung Adenocarcinoma

Identification of Cerna Network Based on a RNA-seq Shows Prognostic Lncrna Biomarkers in Human Lung Adenocarcinoma

Identification of The Potential Signature Genes Between Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Identification of prognostic genes in lung adenocarcinoma immune microenvironment

A Novel Strategy of Integrated Microarray Analysis Identifies CENPA, CDK1 and CDC20 As a Cluster of Diagnostic Biomarkers in Lung Adenocarcinoma.

Identification of dysregulated long non-coding RNAs/microRNAs/mRNAs in TNM I stage lung adenocarcinoma.